Donor stem cell infusion for Crohn's disease or ulcerative colitis
Tests donor stem cells given into a vein in people with inflammatory bowel disease.
Plain-language title generated from the registry record
Registry title: Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for Crohn's Disease or Ulcerative Colitis
Key facts
- Where
- Athens, GreeceSee the site
- Phase
- Phase 1
Where in Greece
- Prodromos Stem Cell InstituteAthens, GreeceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The Foundation for Orthopaedics and Regenerative Medicine
- Trial code
- NCT05003947
- Record updated
- 20 October 2026
- Original description
This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells for the treatment of Crohn's Disease or Ulcerative ColitisRead full original descriptionShow less
Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Crohn's Disease or Ulcerative Colitis
This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells for the treatment of Crohn's Disease or Ulcerative Colitis
Inclusion: Diagnosis of Crohn's disease or Ulcerative Colitis; Understanding and willingness to sign a written informed consent document.
Exclusion: Continued drug abuse; Previous organ transplant; Active infection; Active cancer; Chronic multisystem organ failure; Medical condition that would (based on the opinion of the investigator) compromise patient's safety; Hypersensitivity to sulfur; Clinically significant Abnormalities on pre-treatment laboratory evaluation; Pregnancy; Pre-menopausal women not using contraception.